Canada markets open in 3 hours 51 minutes

HCM Nov 2024 12.500 put

OPR - OPR Delayed Price. Currency in USD
Add to watchlist
0.65000.0000 (0.00%)
As of 10:09AM EDT. Market open.
Full screen
Loading interactive chart...
  • GlobeNewswire

    HUTCHMED to Announce 2024 Half-Year Financial Results

    HONG KONG and SHANGHAI and FLORHAM PARK, N.J., June 26, 2024 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM; SEHK:13) will be announcing its interim results for the six months ended June 30, 2024 on Wednesday, July 31, 2024 at 7:00 am Eastern Daylight Time (EDT) / 12:00 noon British Summer Time (BST) / 7:00 pm Hong Kong Time (HKT). Analysts and investors are invited to join a conference call and audio webcast presentation with Q&A, conducted by HUTCHMED management. Th

  • GlobeNewswire

    Save the Date: HUTCHMED to Present R&D Updates on July 9, 2024

    — HUTCHMED will host in-person presentation and online webinar on Tuesday, July 9 —HONG KONG and SHANGHAI and FLORHAM PARK, N.J., June 24, 2024 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that it will host a R&D update in Shanghai, China, and via webcast on Tuesday, July 9, 2024. During the event, the senior management team will share insights into the Company’s R&D strategy and vision. Additionally, the team will provide updates on certain

  • GlobeNewswire

    HUTCHMED Announces European Commission Approval for FRUZAQLA® (fruquintinib) Received by Takeda

    — Approval for previously treated metastatic colorectal cancer based on results from positive, global, Phase III FRESCO-2 Trial — — FRUZAQLA® (fruquintinib) is the first novel targeted therapy in the EU for metastatic colorectal cancer regardless of biomarker status in over a decade — HONG KONG, SHANGHAI and FLORHAM PARK, N.J., June 21, 2024 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that its partner Takeda (TSE:4502/​NYSE:TAK) has receive